2025年10月19日,科伦博泰宣布,在2025年ESMO年会上,张力教授公布了靶向TROP2的ADC药物芦康沙妥珠单抗用于EGFR突变非小细胞肺癌的III期OptiTROP-Lung04研究结果,该结果同步发表于《新英格兰医学杂志》。研究积极结果支持芦康沙妥珠单抗获NMPA批准上市,用于治疗经EGFR-TKI治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌成人患者。研究中,...
Source Link2025年10月19日,科伦博泰宣布,在2025年ESMO年会上,张力教授公布了靶向TROP2的ADC药物芦康沙妥珠单抗用于EGFR突变非小细胞肺癌的III期OptiTROP-Lung04研究结果,该结果同步发表于《新英格兰医学杂志》。研究积极结果支持芦康沙妥珠单抗获NMPA批准上市,用于治疗经EGFR-TKI治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌成人患者。研究中,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.